MONOVISC®

Order MONOVISC® Online — Single-Injection HA Viscosupplementation for Knee OA

MONOVISC® by Anika Therapeutics is an FDA-approved single-injection hyaluronic acid viscosupplement for the management of knee osteoarthritis pain. Each treatment delivers 88 mg of ultra-pure, cross-linked, non-avian HA in a 4 mL prefilled syringe, completing a full treatment cycle in one clinic visit. Medical Spa Rx stocks MONOVISC® with secure online ordering and both bulk and individual options for licensed practitioners. Buy MONOVISC® online below, in single units or volume quantities.

Why Practitioners Buy MONOVISC® Over Other Viscosupplements

MONOVISC®’s single-injection format is the reason most practices stock it. Multi-injection courses require patients to return for three, four, or five consecutive weekly appointments, and that schedule creates real compliance barriers for osteoarthritis sufferers managing mobility limitations, transport difficulties, or inflexible work commitments [4]. Attrition tends to show up around the third appointment, which is late enough that the patient has absorbed most of the cost and early enough that they may not get the benefit. Removing the return visits removes that failure mode, and for the clinic it means simpler scheduling and less appointment tracking.

What makes the format viable rather than merely convenient is the formulation carrying it. A single dose has to do the work of a full course, and MONOVISC®’s ultra-pure, non-avian, cross-linked HA is supported by randomized, double-blind, placebo-controlled trial data showing statistically significant improvement from baseline in pain and functional outcomes [1]. Coverage follows the evidence: MONOVISC® falls under certain Medicare viscosupplementation policies subject to current LCD and patient eligibility, which is what makes the single-visit protocol practical for practices carrying high insurance volumes [5].

About MONOVISC® — Single-Injection Viscosupplementation for Knee Osteoarthritis

MONOVISC® is FDA-approved for treating pain associated with knee osteoarthritis in adults who have not achieved adequate relief from conservative therapies or simple analgesics. Each treatment cycle consists of a single 4 mL intra-articular injection containing 88 mg of ultra-pure, cross-linked, non-avian sodium hyaluronate at a concentration of 22 mg/mL [4].

Within Anika Therapeutics’ HA portfolio, MONOVISC® is the single-injection option and ORTHOVISC® is its multi-injection counterpart, sharing the same proprietary non-avian HA platform but administered across three to four weekly sessions [2][4]. Having both in one formulation family gives practitioners a choice of regimen without changing the underlying material, and in our experience patient compliance history, not clinical response data, is usually what decides between them.

How MONOVISC® Works — Ultra-Pure HA and Joint Lubrication

In a healthy knee, synovial fluid is rich in endogenous hyaluronic acid, providing lubrication between articular surfaces and viscoelastic cushioning under mechanical load. As osteoarthritis progresses, the concentration and molecular weight of that native HA decline, reducing synovial fluid viscosity and leaving cartilage increasingly exposed to friction-related damage and pain [1][4].

MONOVISC® gel injection addresses this directly. A single intra-articular injection supplements the hyaluronic acid naturally present in the knee joint, replenishing the lubricating properties of synovial fluid and restoring some capacity to absorb mechanical stress. The ultra-pure, cross-linked formulation delivers sustained viscosupplementation from one dose, with randomized, double-blind, placebo-controlled trial data confirming meaningful improvement from baseline in both pain and functional scores, lasting several months in many patients [1].

Is MONOVISC® a Steroid?

MONOVISC® contains only ultra-pure hyaluronic acid and is classified as a medical device rather than a corticosteroid or pharmaceutical [4]. The mechanism is biomechanical rather than pharmacological, and onset and duration differ meaningfully from corticosteroid injections [3]. Patients transitioning from steroid therapy should be counseled on that difference before treatment, since the expectation of rapid relief is the most common source of disappointment with HA viscosupplementation.

About the Manufacturer — Anika Therapeutics

Anika Therapeutics is a US-based medical technology company headquartered in Woburn, Massachusetts, with a commercial and research focus on joint preservation and regenerative medicine. Its viscosupplementation portfolio spans MONOVISC®, ORTHOVISC®, and CINGAL®, products sharing the same proprietary non-avian HA manufacturing platform while serving different clinical protocols and patient profiles [4].

That sustained investment across both single- and multi-injection formats is what separates a specialist manufacturer from a company with one viscosupplement in a broader catalog.

MONOVISC® Product Spotlight

MONOVISC® 88 mg/4 mL is a prefilled syringe containing 88 mg of ultra-pure, cross-linked, non-avian sodium hyaluronate at 22 mg/mL, ready for direct intra-articular administration without reconstitution [4]. MONOVISC® dosage is fixed at that single volume, so there is no dilution decision and no partial-course arithmetic. The prefilled format also simplifies receiving: shipping arrives as individual units rather than course packs, and stock counts run per patient.

A single 4 mL syringe constitutes a complete treatment course, replacing what would otherwise be three to five separate clinic visits. Patients may receive additional cycles as symptoms recur over time, but each cycle requires only one injection.

Practitioners should consult the current MONOVISC® IFU for full specifications on handling, storage, and administration [4]. Clinics that also run aesthetic services can buy HA dermal fillers on the same order, which for practices splitting a single supplier account across two service lines is usually the point of consolidating.

What to Know Before You Buy MONOVISC® Wholesale

MONOVISC® injection price works differently from multi-injection products. A course is one syringe, so the per-patient cost is the per-unit cost, with no course arithmetic and no partial-course waste if a patient stops attending. That makes budgeting straightforward, though it also means the headline unit price looks high against products quoted per syringe across a three-injection course. The comparison only holds at course level.

Practices that buy MONOVISC® wholesale order per patient rather than per course, which changes how stock turns over. There is no partially used course sitting in the fridge and no patient mid-schedule when supply runs short. For clinics running unpredictable knee OA volume, that predictability is worth as much as the unit price.

Treatment Areas and Patient Indications of MONOVISC® Injection

MONOVISC® is indicated for adults with symptomatic knee osteoarthritis who have not responded adequately to conservative, non-pharmacological treatment or standard analgesic use [1][4]. The patients who benefit most are those seeking improvement lasting several months who also have a strong preference for minimizing clinic visits, along with those unlikely to complete a multi-injection course because of mobility, logistical, or personal constraints.

The FDA-approved indication covers the knee joint. Clinical literature references intra-articular HA use in the hip, shoulder, and ankle, but administering MONOVISC® outside the knee is off-label and requires appropriate patient consent and institutional documentation. Licensed practitioners looking to buy orthopedic injections for knee OA management can add MONOVISC® to a Medical Spa Rx order alongside the rest of the viscosupplement range.

Practices covering both orthopedic and aesthetic indications can buy dermal fillers on the same account, which for clinics splitting one supplier relationship across two service lines is usually the reason to consolidate.

MONOVISC® Injection Administration and Aftercare

MONOVISC® is delivered as a single intra-articular injection into the synovial space of the knee using accepted aseptic technique. Where significant joint effusion is present, it should be fully aspirated before injection, since diluting the HA formulation may reduce clinical effectiveness. How MONOVISC® is administered does not vary with presentation, since the syringe arrives ready to use and shipping conditions do not require reconstitution planning at the point of care. The entire 4 mL syringe volume goes in during one session, and ultrasound guidance is available at the practitioner’s discretion to optimize needle placement [4].

How long it takes for a MONOVISC® injection to work varies between patients. Trial data indicate that pain relief in the knee with MONOVISC® typically becomes measurable within the first several weeks post-injection, with many patients reporting meaningful osteoarthritis knee pain relief across that window [1]. Patients with more advanced joint degeneration may see a longer or more modest response. Setting that expectation at consultation matters more here than with faster-acting alternatives, because the single-visit format gives no second appointment at which to reset it.

For MONOVISC® injection aftercare, patients should avoid high-impact or strenuous activity, including running, heavy gym work, and prolonged weight-bearing, for 48 hours after the procedure. MONOVISC® injection recovery time is brief for most patients, with localized injection-site discomfort typically resolving within one to two days [4].

MONOVISC® Safety Profile — Side Effects and Contraindications

MONOVISC® knee injection has a well-characterized tolerability profile consistent with intra-articular HA therapy. The most commonly reported side effects of MONOVISC® injection are localized and transient: injection-site pain, swelling, warmth, and mild redness following treatment [1][4].

These post-injection reactions are self-limiting for most patients and resolve within two to three days without intervention, which is a physiological response to intra-articular injection rather than an indicator of treatment failure.

Less commonly, patients may experience an acute local joint reaction with more pronounced swelling and pain. That should prompt clinical review to exclude infection before the response is attributed to the HA injection. Contraindications include known hypersensitivity to hyaluronic acid or any formulation excipient, active infection within the target joint, and skin infection or disease at the proposed injection site. Significant joint effusion calls for aspiration before injection rather than ruling treatment out, provided nothing else is of concern.

Practitioners should review the full MONOVISC® IFU for complete information on contraindications, precautions, and adverse events before administering treatment [4].

Regulatory Status and Coverage

MONOVISC® is FDA-approved through the PMA pathway under application P090031, with an approved indication for treating pain in adults with knee osteoarthritis [4]. As a medical device rather than a pharmaceutical, it follows a regulatory pathway that carries through to procurement, clinical documentation, and patient communication.

MONOVISC® Medicare Coverage

MONOVISC® is covered under certain viscosupplementation policies subject to current LCD and patient eligibility per Local Coverage Determination L39260 [5]. Practitioners billing Medicare should confirm the relevant HCPCS codes and check the current LCD version before treatment, since coverage determinations are revised periodically. Commercial insurance coverage for viscosupplementation is also widely available, though verifying the individual plan before treatment remains the only reliable way to avoid unexpected patient liability. Practices that purchase MONOVISC® online should keep coverage documentation with the order record, since LCD revisions can affect claims filed after stock was acquired.

MONOVISC® Knee Injection vs Competing Viscosupplements

MONOVISC® vs ORTHOVISC®

Clinics that already buy ORTHOVISC® are working with the same non-avian ultra-pure HA platform from the same manufacturer, which makes this the cleanest substitution available. ORTHOVISC® runs three to four weekly injections; MONOVISC® delivers the equivalent course in one visit [2][4]. Where a patient responds to HA viscosupplementation but keeps missing appointments, switching between the two changes the protocol without changing the material.

MONOVISC® vs SYNVISC®

Both categories offer a single-injection route, so visit count does not separate them. SYNVISC® and SYNVISC-ONE® use hylan G-F 20, cross-linked HA derived from avian sources, against MONOVISC®’s fermentation-derived non-avian material [2]. Practices keeping an avian single-injection option on hand buy SYNVISC® for patients with no sensitivity history and established response to it; source and molecular architecture are the only variables in play.

MONOVISC® vs EUFLEXXA®

Neither product requires avian protein allergy screening, since both draw on non-avian biofermentation-derived HA. Schedule is the difference: three weekly injections against one [2]. A practice that wants to buy EUFLEXXA® is usually choosing the graduated course deliberately, for patients where two additional assessment points during treatment are worth the extra visits.

MONOVISC® vs HYALGAN®

Decades of controlled clinical trial data are HYALGAN®’s argument, and for practitioners who weight evidence volume heavily it is a strong one. MONOVISC® counters with the non-avian formulation and the single visit rather than with a deeper file. Clinics carrying both across the avian and non-avian sides of the category can buy HYALGAN® from the same catalog.

MONOVISC® vs SUPARTZ®

SUPARTZ® sits furthest from MONOVISC® on both axes that matter here, avian-derived and administered across three to five weekly injections. The screening requirement and the multi-visit schedule come as a package, though practices with high-attendance patient populations may still buy SUPARTZ® at a lower per-unit cost and accept both.

MONOVISC® vs DUROLANE®

DUROLANE® is the closest peer, since both are non-avian HA products built to complete a treatment cycle in one intra-articular injection. Molecular weight, degree of cross-linking, and HA concentration are where they diverge. Selection usually reflects familiarity with the respective clinical data and existing formulary commitments rather than a decisive clinical advantage.

FAQs

What is MONOVISC®?

MONOVISC® is an FDA-approved single-injection HA viscosupplement from Anika Therapeutics, delivering 88 mg of ultra-pure, cross-linked, non-avian hyaluronic acid in a 4 mL prefilled syringe [1][4]. It is indicated for knee osteoarthritis pain in adults who have not responded to conservative therapy, and completes a treatment cycle in one clinic visit.

Is MONOVISC® a one-time injection?

Yes, per treatment cycle. One injection per visit is the defining differentiator from multi-injection viscosupplements such as ORTHOVISC® at three to four injections or SUPARTZ® at three to five [4]. Patients may undergo repeat cycles as symptoms recur, but each cycle requires only one visit.

How does MONOVISC® work?

MONOVISC® supplements the hyaluronic acid naturally present in the knee’s synovial fluid, which depletes as osteoarthritis progresses [1][4]. Restoring HA concentration improves joint lubrication and cushioning, reducing friction between articular surfaces and easing OA-related pain. It is a hyaluronic acid medical device with a biomechanical rather than pharmacological mechanism.

Is MONOVISC® a steroid?

No. MONOVISC® contains only hyaluronic acid and is classified as a medical device, not a corticosteroid [4]. Patients who have previously received steroid injections should be told MONOVISC® works differently, with gradual onset over weeks rather than a rapid anti-inflammatory response [3].

How long does it take for a MONOVISC® injection to work?

Onset varies by individual. Randomized, double-blind, placebo-controlled trial data show improvement in pain scores from baseline, typically within the first few weeks following injection [1]. Set clear patient expectations at treatment, distinguishing the progressive onset from faster-acting alternatives. Practitioners asking how long it takes for MONOVISC® to start working should frame the answer in weeks rather than days.

How long do MONOVISC® injection side effects last?

Injection-site reactions including localized pain, swelling, and warmth are the most common side effects and are generally transient, resolving within two to three days in most patients [1][4]. Patients should rest the joint and avoid strenuous activity during that period. Severe or prolonged symptoms warrant clinical assessment.

Does Medicare cover MONOVISC®?

MONOVISC® is covered under certain Medicare viscosupplementation policies, subject to current LCD and patient eligibility per Local Coverage Determination L39260 [5]. Verify the current LCD version and confirm individual patient eligibility before proceeding.

What do MONOVISC® injection reviews say about outcomes?

Practitioner and patient reports vary, which is expected given that response depends on OA severity, joint condition, and individual factors. The more reliable picture comes from controlled data: randomized, double-blind, placebo-controlled trial evidence shows statistically significant improvement from baseline in pain and functional scores, with benefit lasting several months in many patients [1]. Anecdotal reports are worth reading in that context rather than in place of it.

Trying to buy MONOVISC® online?

Medical Spa Rx provides a secure, verified route to buy MONOVISC® injection online for licensed practitioners and clinic procurement teams. Add the 88 mg/4 mL prefilled syringe to your cart, select individual units or bulk quantities, and order MONOVISC® online through our encrypted checkout. Volume pricing applies to higher-quantity orders, and all orders are fulfilled to verified healthcare professionals in line with applicable regulations.

Resources

1. Petterson SC, Plancher KD. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. Knee Surgery, Sports Traumatology, Arthroscopy. 2019. https://pubmed.ncbi.nlm.nih.gov/30159738/
2. Altman RD, Bedi A, Karlsson J, Sancheti P, Schemitsch E. Product Differences in Intra-articular Hyaluronic Acids for Osteoarthritis of the Knee. American Journal of Sports Medicine. 2015. https://doi.org/10.1177/0363546515609599
3. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis & Rheumatology. 2009. https://pubmed.ncbi.nlm.nih.gov/19950318/
4. Anika Therapeutics, Inc. MONOVISC® Product Information and Instructions for Use / FDA PMA Summary (P090031). www.accessdata.fda.gov/cdrh_docs/pdf9/P090031b.pdf and www.accessdata.fda.gov/cdrh_docs/pdf9/P090031d.pdf
5. Centers for Medicare & Medicaid Services (CMS). Hyaluronic Acid Injections for Knee Osteoarthritis. Local Coverage Determination L39260. Updated 07/01/2022. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39260&ver=5

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.